Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis

Area of Science:

• Pediatric infectious diseases
• Clinical pharmacology
• Antimicrobial stewardship

Background:

• Acute hematogenous osteomyelitis (AHO) is a serious bone infection in children.
• Daptomycin is a lipopeptide antibiotic with activity against Gram-positive bacteria.
• Evaluating novel antibiotic options for pediatric infections is crucial.

Purpose of the Study:

• To prospectively evaluate the efficacy and safety of daptomycin compared to an active comparator in children with AHO.
• To determine if daptomycin meets prespecified noninferiority margins for treating AHO.

Main Methods:

• A randomized, controlled, double-blind, global, multicenter, phase 3 trial.
• Involved 1-17 year olds with suspected/confirmed AHO requiring intravenous therapy.
• Compared intravenous daptomycin (once-daily) to vancomycin, nafcillin, or equivalent for at least 4 days, followed by oral therapy.

Main Results:

• Clinical improvement by Day 5 was observed in 78% of daptomycin-treated patients and 83% of comparator-treated patients (not statistically significant).
• Daptomycin did not meet the prespecified 15% noninferiority margin.
• Adverse events were less frequent in the daptomycin arm (46%) compared to the comparator arm (63%).

Conclusions:

• Daptomycin did not meet noninferiority criteria for AHO treatment in children, despite comparable clinical improvement rates.
• The study could not evaluate daptomycin for MRSA AHO due to insufficient cases.
• The trial design provides insights for future pediatric AHO studies.